Investigational drug · Phase 3
Pyrotinib
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Non-small Cell Lung Cancer, HER2-expressing Advanced Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
213
Any phase or sponsor naming "Pyrotinib"
First trial start
2019
Jul 12, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pyrotinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Non-small Cell Lung Cancer
- HER2-expressing Advanced Solid Tumors
- HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Pyrotinib" as an intervention, largest first.
- A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03980054 · 2,135 participants · Start Jul 12, 2019 · Primary completion Jun 2027
Drug: Pyrotinib; Placebo · For: Breast Cancer
Sites: Shanghai, China
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation ModelPivotal-lookingNot yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07239271 · 2,000 participants (planned) · Start Nov 16, 2025 · Primary completion Dec 2027
Drug: The control group; Adaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response · For: Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
- Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05861271 · 1,008 participants (planned) · Start Jun 1, 2023 · Primary completion Jul 1, 2026
Drug: Capecitabine,Pyrotinib · For: Breast Cancer Stage I
Sites: Shanghai, China
Peking Union Medical College HospitalAcademic, hospital or other
NCT05680194 · 1,000 participants (planned) · Start Apr 1, 2022 · Primary completion Mar 31, 2025
Drug: Bisphosphonate · For: Breast Cancer Female
Sites: Beijing, China
- The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical StudyPivotal-lookingRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT06958627 · 964 participants (planned) · Start Apr 30, 2024 · Primary completion Apr 30, 2025
Drug: pyrotinib · For: HER2 Positive Breast Cancer; Pyrotinib Treatment
Sites: Beijing, China
- Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT05841381 · 876 participants (planned) · Start May 6, 2023 · Primary completion May 6, 2028
Drug: Pyrotinib; Trastuzumab and 1 more · For: Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT04423185 · 770 participants (planned) · Start Aug 15, 2020 · Primary completion Jul 1, 2026
Drug: Almonertinib 110 MG; Dacomitinib 45 MG and 9 more · For: Rare Tumor
Sites: Beijing, China
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast CancerPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03863223 · 590 participants · Start Apr 22, 2019 · Primary completion Dec 30, 2022
Drug: Pyrotinib, Trastuzumab, Docetaxel; Placebo, Trastuzumab, Docetaxel · For: Metastatic Breast Cancer
Sites: Beijing, China
- Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast CancerPivotal-lookingRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT04646759 · 516 participants (planned) · Start Oct 14, 2020 · Primary completion Dec 14, 2028
Drug: Fulvestrant combined with Pyrotinib; Capecitabine combined with Pyrotinib · For: Breast Cancer
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study.
Chen Z, Jing H, Huang S, et al. · Clin Transl Radiat Oncol 2027
- Targeting an ASCL1-WNT11-ERK feed-forward loop to overcome pyrotinib resistance in HER2-positive breast cancer.
Yin F, Zhou B, Li Y, et al. · Mater Today Bio 2026
- Recent advances in HER2-targeted inhibitors for cancer therapy.
Zhu W, Lu X · Pharm Sci Adv 2026
- Palbociclib, Fulvestrant, Trastuzumab, and Pyrotinib for Patients with Advanced Breast Cancer with Brain Metastases: A Prospective Multicenter Phase 2 Trial.
Chen D, Wang N, Xu F, et al. · Clin Cancer Res 2026
- Experience with pyrotinib monotherapy for advanced HER2-positive breast cancer with diffuse hepatic metastases and severe hepatic dysfunction: a case report.
Jiang S, Zhang N, Zhang T, et al. · Int J Surg Case Rep 2026
- Real-world comparative outcomes of pyrotinib-based versus pertuzumab-based first-line therapy in HER2-Positive advanced breast cancer: a multicenter retrospective cohort study from Xinjiang, China.
Hujiahemaiti Y, Ge Y, Zhang C, et al. · Front Pharmacol 2026
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.